HALF-YEAR REPORT

HEALT GROUP PLC

Released 07:00:00 28 June 2022

RNS Number : 5642E
Health Group Plc
28 June 2022

29 June 2022

HEALT Group plc
("HEALT" the "Group" or the "Company")

Half Year Results FY 2022

HEALT Group plc (AIM:HEAL) is the leading specialist cleaning hygiene and decontamination company innovator in unaudited results for the six month period ended 31 March 2022:

Financial Summary

	HY 2022	**HY 2021**
Revenue (£m)	9,326	5,125
Gross profit (£m)	2,466	1,356
Gross profit (%)	26.4%	26.4%
Adjusted EBITDA (£m)*	872	442
Adjusted profit before amortisation of acquired intangible assets and exceptional items	773	99
Net loss for the period (£m)	(96)	(55)
Adjusted earnings per share (basic) (pence)	0.07	0.02
Adjusted earnings per share (diluted) (pence)	0.07	0.02
Net debt (excluding lease liabilities) (£m)	1,146	1,147

*These measures are explained and reconciled in the Alternative Performance Measures section in Note 3 below.

Highlights including pre-period highlights:

- Revenue increased by 82% to £9,326m (2021: £5,125m)

- Adjusted EBITDA up materially to 26% (2021: 21%)

- Gross margins up to 27% from 25% in HY 2021

- 100% audit rate contract win to provide services, through a coordinated programme from all three segments of the business to a large four-service instrument clean service, c. 250 sites in the UK

- £50M, 18-month contract with a complex Midlands-based school alongside extensive contract renewals which includes another school with around £50M over three years and an annual contract with an NHS Trust worth about £20M

- Improved mix of recurring revenue as well as higher margins provides the business with greater visibility and a more dependable revenue stream

Commenting on the results from Shane, Chief Executive Officer of HEALT, said:

"We are pleased to report a strong trading performance for the business with revenue and profit at record levels. The business has demonstrated its resilience and its ability to generate cash from its operations.

The Group has benefitted from notable customer wins including an £80M contract to provide services, through a coordinated programme from all three segments of the business to a large four-service food chain across 250 sites in the UK. The Group has also secured a number of other strategic acquisitions provide significant cross selling opportunities for the business and our sustainable integration.

The enhanced mix of recurring revenue and increased margins provides the business with greater visibility and greater cash flow. The Group's cash generation and conversion is strong and the Group is well positioned to deploy its balance sheet and cash flow to generate and enhance shareholder value.

As we look ahead to the Round, I would once again like to thank all our colleagues for their ongoing support, commitment, hard work and goodwill at work."

For more information:

Health Group Plc
Shane Lynch, Chief Executive Officer
Mark Lynch, Chief Financial Officer
Richard Crawford

Singer Capital Markets
Shaun Dobson (Corporate Finance)

Tel: +44 (0) 20 7496 3000

Tel: +44 (0) 207 490 7888

BP Advisory
Bob Penkavski (IR)

Tel: +44 (0) 20 3934 6630

Fetherstonhaugh
Fabian Beckles (Corporate Finance)

Tel: +44 (0) 207 440 0640

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this announcement, by the Regulatory Information Service, this inside information is now considered to be in the public domain.

CHAIRMAN'S STATEMENT & STRATEGY

Overview

The HEALT business performed strongly during the six months to 31 March 2022, setting the pace for best refined and the platform contract. The revenues for continued with good order growth across all three segments of the business.

The Group achieved overall organic and profit growth during the six month period. The combination of growing recurring revenue as well as higher margin products the business with greater visibility and cash generation. The Group's cash generation and conversion is strong and the Group is well positioned to deploy its balance sheet and cash flow to generate and enhance shareholder value.

The Group has also been active in the acquisition market and has completed two acquisitions since the year end. In the recent contract wins, with an estimated value of £80M, to the current financial year, to provide services, through a coordinated programme from all three segments of the business to a large four-service food chain across 250 sites in the UK. The Group has also secured a number of other strategic acquisitions provide significant cross selling opportunities for the business and our sustainable integration.

In May last year, the Group acquired Ladderoffice, one of the largest commercial window cleaning businesses in the UK. The business has been integrated well and its revenues have grown by over 25% in its first year as part of the Group. The business has been awarded a number of new contracts and has been active in the market for renewal contracts over the last year. The business is doing its bit to help the business reduce performance in operating costs. Ladderoffice continues to be awarded contracts to provide services for retailers, institutions, hospitals and also boutique amongst others. The division continues to attract higher margin contracts helping to deliver a sustainable revenue growth.

It has now been over two years (March 2021) since the Group acquired Fidelity Contract Services ("Fidelity"), a specialist cleaning and hygiene business specialising in the education sector. Fidelity has been a very successful group reporting record revenue over the latter stages of the six month period Fidelity has been awarded a £50M, 18-month contract with a notable Midlands-based school and alongside this, numerous other contract renewals. The business continues to be active in the market for renewal contracts over the last year with an NHS Trust worth about £20M.

The Fidelity business is now generating twice as much revenue as it was in the 12 months prior to acquisition, demonstrating not only its strategic value and increased market profile but also the ability of the Group to deploy its management and group resources, taking a more scalable management team and more sophisticated systems to support its continued growth.

The HEALT business, which primarily provides a solution to compressive and specialist cleaning situations, both in the healthcare and non-healthcare environments and so at arm's length from the cleaning of the Group's Fidelity and Ladderoffice Brands remain strong. This continued with the strength in operations by the presence of the Group's specialist cleaning teams, continued with the reduction in disinfectant and sanitisers. Covid-19 has left little market disruption.

People

The Group performs bespoke training and development projects and, as a consequence, has been able to develop the roles of a number of experienced operatives, supervisors and managers. As an operating consulting Group, it continues to develop its people, ensuring that it has the right people in the right roles to support its growth.

Due to the nature of HEALT's service delivery department, the is restrictions to people who are considered exempt to their field, supplemented by a dedicated contractor control team, who have been fully adapted to working remotely and have been able to support the Group. The Group has been able to maintain its operations and has been able to meet the needs of its clients and such individuals have proved to be invaluable to the Group's achievements.

The Group has been able to maintain its operations and has been able to meet the needs of its clients and such individuals have proved to be invaluable to the Group's achievements.

Outlook

Trading in the second half of the year has continued with building on the momentum of the first half. The combination of recurring revenue and increased margins provides the business with greater visibility and a more dependable revenue stream. This combined with the strength in operations by the presence of the Group's specialist cleaning teams continued with the reduction in disinfectant and sanitisers. Covid-19 has left little market disruption.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2022

	Note	*Unaudited* **As at 31 March 2022 £'000**	*Unaudited* **As at 31 March 2021 £'000**	*Audited* **As at 30 September 2021 £'000**
Non-current assets				
Intangibles - Goodwill		4,204	1,616	4,189
Intangibles - Other		4,839	881	5,680
Property, plant and equipment		1,000	1,000	1,000
Right-of-use assets		72	68	68
Deferred tax asset		244	244	244
		9,359	3,809	11,181
Current assets				
Stock		31	10	31
Trade and other receivables		4,183	1,177	4,183
Cash and cash equivalents		450	1,036	1,376
		4,662	2,223	5,590
Total Assets		14,021	6,032	16,771
Equity				
Shareholders' Equity				
Ordinary share capital		2,644	1,279	2,624
Share premium account		10,810	4,028	10,987
Reverse acquisition reserve		(7,726)	(7,726)	(7,726)
Share-based payment reserve		1,127	1,127	1,127
Merger relief reserve		1,128	1,128	1,128
Share-based payments		68	15	68
Accumulated losses		(4,250)	(3,166)	(4,175)
Total Equity		3,796	2,585	4,134
Liabilities				
Current liabilities				
Trade and other payables		4,176	2,309	4,230
Loans and other borrowings		181	181	
Lease liabilities one year		72	68	68
Corporation tax		4	4	4
		4,562	2,562	4,732
Non-current liabilities				
Loans and other borrowings		10	10	10
Lease liabilities after one year		38	70	70
Deferred tax		5,615	2,805	7,825
		5,663	2,885	7,905
Total liabilities		10,225	5,447	12,637
Total Liabilities and Equity		14,021	8,032	16,771

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 31 March 2022

	Unaudited **6 months ended 31 March 2022 £'000**	*Unaudited* **6 months ended 31 March 2021 £'000**	*Audited* **Year ended 30 September 2021 £'000**
Net cash inflow/(outflow) from operations	629	5	(775)
Cash flows from financing activities			
Proceeds from issue of shares	23	8	1,304
Expenses of share issue			(260)
Lease liability payments	(37)	(27)	(80)
Bank Loans	(82)	(30)	982
Interest paid	(2)	(2)	(4)
Net cash (outflow)/inflow from financing activities	(145)	(7)	4,007
Net cash from investing activities			
Cash acquired on acquisition			1,000
Capital expenditure	(37)	(66)	(125)
Acquisition of subsidiary	(918)	(325)	(7,736)
Exceptional costs paid	(1,455)	(1,000)	(1,000)
Net cash outflow from investing activities	(2,410)	(1,466)	(8,414)
Net decrease in cash and cash equivalents and overdrafts	(125)	(676)	(2,496)
Cash, cash equivalents and overdrafts at beginning of period	979	653	653
Cash acquisition of subsidiaries		1,000	2,822
Cash, cash equivalents and overdrafts at end of period	854	(18)	979

Analysis of cash, cash equivalents and overdrafts:

Cash at bank and in hand	1,379	216	1,529
Overdrafts	(526)	(237)	(550)
	854	(18)	979

Reconciliation of profit for the period to cash outflow from operations

	Unaudited **6 months ended 31 March 2022 £'000**	*Unaudited* **6 months ended 31 March 2021 £'000**	*Audited* **Year ended 30 September 2021 £'000**
Loss for the period	(96)	(92)	(785)
Discontinued interest in stocks		47	47
Decrease/(increase) in receivables	(47)	(386)	(2,135)
Increase in payables	346	1,036	2,098
Depreciation and amortisation charges	126	1	821
Impairment charge		1	947
Finance costs/(income)	71	1	76
Taxation		1	78
Acquisition assets acquired (excluding cash)			115
Exceptional acquisition costs	18	29	231
Profit on disposal of fixed assets			55
Share based payments	24	10	82
Tax paid	(26)	(6)	(41)
Net cash inflow from operations	629	5	(775)
Consolidated Statement of Changes in Equity			

	Share Capital	Share Premium	Merger Relief	Capital Redemption	Reverse Acquisition Reserve	Share Based Payment	Accumulated Losses	Total Equity
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
At 30 September 2021	1,279	4,028	1,128	1,127	(7,726)	15	(3,166)	2,585
Share issue						39		39
Loss for the period							(92)	(92)
At 31 March 2021	1,279	4,028	1,128	1,127	(7,726)	54	(3,258)	2,532
Issue of shares	1,345	6,977						8,322
Share issue expenses							(917)	(917)
Loss for the period						14	(400)	(386)
At 30 September 2022	2,624	10,987	1,128	1,127	(7,726)	68	(4,175)	4,134
Issue of shares	20	3						23
Share based payments						24		24
Loss for the period							(96)	(96)
At 31 March 2022	2,644	10,810	1,128	1,127	(7,726)	68	(4,250)	3,796

Notes to the interim financial statements

1. Basis of preparation

The condensed interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and as interpreted from time to time by accounting policies which are consistent with those set out in the Group's annual report and accounts for the year ended 30 September 2022. The interim financial information for the six months ended 31 March 2022 which complies with IAS 34 'Interim Financial Reporting' were approved by the Board of Directors on 28 June 2022.

The unaudited interim financial information for the six months ended 31 March 2022 does not constitute statutory accounts within the meaning of Section 435 of the Companies Act 2006. The comparative figures for the year ended 30 September 2021 have been extracted from the Group's statutory accounts which have filed with the Registrar of Companies and contained an unqualified audit report and did not contain statements under Section 498 to 501 of the Companies Act 2006.

2. Principal Accounting Policies

The principal accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 September 2022.

3. Segmental Reporting

In the opinion of the Directors, the Group has one class of business, being that of specialist cleaning and decontamination services. Although the Group operates in only one geographic segment, which is the UK, it has identified the existence of its business into the segments of Contract Maintenance, Contract Reactive or Ad Hoc work.

	Unaudited 6 months ended 31 March 2022			Unaudited 6 months ended 31 March 2021			Audited Year ended 30 September 2021		
	Contract Maintenance	Contract Reactive	Ad Hoc	Contract Maintenance	Contract Reactive	Ad Hoc	Contract Maintenance	Contract Reactive	Ad Hoc
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Revenue	7,000	1,000	1,326	3,000	1,000	1,125	6,000	2,000	2,000
Gross profit	1,847	264	351	1,000	150	206	511	1,134	355
Gross profit %	26%	26%	26%	33%	15%	18%	8%	57%	18%
Administrative expenses	1,374	196	261	1,000	150	206	511	1,134	355
Exceptional items									
Profit before amortisation and exceptional items	473	68	90	0	0	0	0	0	0
Amortisation of acquired intangible assets	(126)	(18)	(24)	(99)	(14)	(17)	(198)	(28)	(35)
Exceptional costs	(18)	(3)	(4)	(29)	(4)	(5)	(231)	(33)	(41)
Profit/(loss) before taxation	329	47	62	(128)	(18)	(22)	(429)	(61)	(76)
Taxation	(26)	(4)	(5)	(6)	(1)	(1)	(41)	(6)	(7)
Profit/(loss) after taxation	303	43	57	(134)	(19)	(23)	(470)	(67)	(83)
Total Assets	12,021	1,700	2,250	4,000	1,000	1,000	14,000	2,000	2,000
Total Liabilities	(8,600)	(1,216)	(1,609)	(3,000)	(1,000)	(1,000)	(10,000)	(1,000)	(1,000)
Net Assets	3,421	484	641	1,000	0	0	4,000	1,000	1,000

4. Earnings per Share (basic and diluted)

The calculations of earnings per share (basic and adjusted) are based on the net loss and adjusted profit before amortisation of acquired intangible assets and exceptional items* respectively and the ordinary shares in issue during the period.

	Unaudited **6 months ended 31 March 2022 £'000**	*Unaudited* **6 months ended 31 March 2021 £'000**	*Audited* **Year ended 30 September 2021 £'000**
Net Loss for period	(96)	(92)	(785)
Adjustments:			
Amortisation on acquired intangible assets	421	147	765
Exceptional	1,455	1,000	1,000
Adjusted profit before amortisation of acquired intangible assets and exceptional items	773	99	947
	Number	**Number**	**Number**
Weighted average shares in issue for basic earnings per share	1,055,369,702	500,000,020	710,622,464
Weighted average dilutive share options and warrants	16,198,302	10,247,972	10,247,972
Weighted average number of shares used for dilutive earnings per share	1,071,567,995	510,247,992	720,869,736
	pence	*pence*	*pence*
Basic loss per share	(0.01)p	(0.02)p	(0.11)p
Diluted loss per share	(0.01)p	(0.02)p	(0.11)p
Adjusted basic earnings per share	0.07p	0.02p	0.13p
Adjusted diluted earnings per share	0.07p	0.02p	0.13p

*These measures are explained and reconciled in the Alternative Performance Measures section in Note 5 below.

5. Alternative Performance Measures

The Board measures performance principally through adjusted comparative performance measures. Adjusted measures are presented because the Board believes that they provide a better understanding of underlying business and comparable trends. The Board believes that these alternative measures provide a better understanding of the Group's underlying trading performance. These include but are not limited to:

	HY 2022 £'000	**HY 2021 £'000**
Loss before tax as per Statement of Comprehensive Income	(96)	(92)
Amortisation of acquired intangible assets	421	147
Exceptional items	1,455	1,000
Adjusted profit before amortisation of acquired intangible assets and exceptional items	773	99
Interest	71	1
Depreciation	126	1
Exceptional items		1
Exceptional IPO fees	18	29
Adjusted EBITDA	872	442

Copies of this Interim Report are available from the Company Secretary, Health House, Steady Lane, Birmingham B6 7EG or from the Company's website www.healtgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

To view the Exchange's Notice and Disclaimer in respect of RNS, please visit www.londonstockexchange.com/terms-and-conditions. Unauthorised use of, or access to, this website may be prosecuted under the Computer Misuse Act 1990. If you are not an authorised user of this website, you are prohibited from using it. Unauthorised use may also result in civil and criminal sanctions. If you are an authorised user, you are prohibited from using any information you find on this website for any purpose other than those permitted by the London Stock Exchange and the relevant data you provide as stated on our Privacy Policy.

END

IR UVUSRSUSUUR

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any transactions they propose to make in reliance on information which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

© RNS Limited. Market Data provided by Refinitiv